Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab, Carboplatin, PLD, Pembrolizumab, or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02606305
Recruitment Status : Active, not recruiting
First Posted : November 17, 2015
Last Update Posted : September 12, 2019
Sponsor:
Information provided by (Responsible Party):
ImmunoGen, Inc.

Brief Summary:
This is a phase 1b/2 study to assess the safety, tolerability, and preliminary anti-tumor activity of IMGN853 when administered with chemotherapy. Patients will be assigned to one of five regimens: IMGN853 administered with bevacizumab, IMGN853 administered with carboplatin, IMGN853 administered with pegylated liposomal doxorubicin, IMGN853 administered with pembrolizumab, or IMGN853 administered with bevacizumab+carboplatin

Condition or disease Intervention/treatment Phase
Epithelial Ovarian Cancer Primary Peritoneal Cancer Fallopian Tube Cancer Drug: IMGN853 Drug: Bevacizumab Drug: Carboplatin Drug: Pegylated Liposomal Doxorubicin Drug: Pembrolizumab Drug: Bevacizumab+Carboplatin Phase 1 Phase 2

Detailed Description:
The dose escalation part of the study will assess safety and tolerability and determine the maximum tolerated dose (MTD) for each regimen. The dose expansion of the MTD will assess safety, tolerability and preliminary anti-tumor activity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 264 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Actual Study Start Date : December 2015
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : July 2021


Arm Intervention/treatment
Experimental: Regimen A
Dose escalation and dose expansion with IMGN853 and bevacizumab
Drug: IMGN853
Drug: Bevacizumab
Experimental: Regimen B
Dose Escalation with IMGN853 and carboplatin
Drug: IMGN853
Drug: Carboplatin
Experimental: Regimen C
Dose Escalation with IMGN853 and pegylated liposomal doxorubicin
Drug: IMGN853
Drug: Pegylated Liposomal Doxorubicin
Experimental: Regimen D
Dose escalation and dose expansion with IMGN853 and pembrolizumab
Drug: IMGN853
Drug: Pembrolizumab
Experimental: Regimen E
Dose expansion with IMGN853 and bevacizumab+carboplatin
Drug: IMGN853
Drug: Bevacizumab+Carboplatin



Primary Outcome Measures :
  1. Incidence of TEAEs, SAEs, adverse events, clinically significant changes in laboratory/clinical tests and dose-limiting toxicities (DLTs) as a measure of safety and tolerability [dose escalation] [ Time Frame: Up to 2.5 years ]
  2. Objective response rate (ORR); the proportion of patients achieving a complete response, partial response (CR or PR) according to RECIST1.1 and CA125 evaluations [dose expansion only] [ Time Frame: Up to 2.5 years ]

Secondary Outcome Measures :
  1. Duration of response (DOR); the time from first objective response until progressive disease, will be calculated for all patients who achieve a confirmed objective response (PR or CR) [ Time Frame: Up to 2.5 years ]
  2. Progression-free survival (PFS); the time from date of first dose until the date of objective disease progression or death by any cause as defined by RECIST 1.1. [ Time Frame: Up to 2.5 years ]
  3. PK parameters: maximum plasma concentration (Cmax) of IMGN853, bevacizumab, carboplatin and PLD [ Time Frame: Up to 2.5 years ]
  4. PK parameters: area under the time-concentration curve (AUC) of IMGN853, bevacizumab, carboplatin and PLD [ Time Frame: Up to 2.5 years ]
  5. PK parameters: terminal half-life (t½) of IMGN853, bevacizumab, carboplatin and PLD [ Time Frame: Up to 2.5 years ]
  6. PK parameters: clearance (Cl) of IMGN853, bevacizumab, carboplatin and PLD [ Time Frame: Up to 2.5 years ]
  7. PK parameters: volume of distribution at steady state (Vss) of IMGN853, bevacizumab, carboplatin and PLD [ Time Frame: Up to 2.5 years ]
  8. PK parameters: maximum time (Tmax) of IMGN853, bevacizumab, carboplatin and PLD [ Time Frame: Up to 2.5 years ]
  9. Immunogenicity: Presence of Anti-Drug Antibody (ADA) [ Time Frame: Up to 2.5 years ]
  10. Number of patients with CA125 clinical response. [ Time Frame: Up to 2.5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
  • Folate receptor alpha positive tumor expression as defined in the protocol
  • Willing to undergo tumor biopsy
  • Measurable disease

Exclusion Criteria:

  • Primary platinum-refractory EOC
  • Diagnosis of clear cell, low grade ovarian cancer or mixed tumors
  • Serious concurrent illness or clinically relevant active infection, including known diagnosis of HIV and hepatitis B or C, as defined in the protocol
  • Active autoimmune disease requiring systemic therapy in past 2 years (IMGN853 and pembrolizumab only)
  • Women who are pregnant or breastfeeding
  • Male patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02606305


Locations
Layout table for location information
United States, Alabama
University of Alabama
Birmingham, Alabama, United States
United States, California
University of California at Los Angeles
Los Angeles, California, United States
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, Nevada
City of Hope
Reno, Nevada, United States
United States, Ohio
The Ohio State University
Hilliard, Ohio, United States, 43026
United States, Oklahoma
Peggy and Charles Stephenson Oklahoma Cancer Center
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Belgium
Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg - Leuvens Kankerinstituut
Leuven, Belgium, 3000
Canada
Juravinski Cancer Center
Calgary, Canada
Tom Baker Cancer Center
Hamilton, Canada
Centre Hospitalier de l'universite de Montreal (CHUM)
Montreal, Canada
McGill University Health Center
Montreal, Canada
Princess Margaret Cancer Center
Toronto, Canada
Spain
Hospital Vall D'Hebron
Barcelona, Spain
MD Anderson
Madrid, Spain, 28033
Sponsors and Collaborators
ImmunoGen, Inc.
Investigators
Layout table for investigator information
Study Director: Patrick Zweidler-McKay, MD, PhD ImmunoGen, Inc.

Layout table for additonal information
Responsible Party: ImmunoGen, Inc.
ClinicalTrials.gov Identifier: NCT02606305     History of Changes
Other Study ID Numbers: IMGN853-0402
KEYNOTE PN409 ( Other Identifier: Merck )
First Posted: November 17, 2015    Key Record Dates
Last Update Posted: September 12, 2019
Last Verified: September 2019
Keywords provided by ImmunoGen, Inc.:
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer
IMGN853
ADC
Antibody drug conjugate
ImmunoGen
Antibody
Phase 1
Folate receptor alpha
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Fallopian Tube Diseases
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Bevacizumab
Pembrolizumab
Carboplatin
Doxorubicin
Liposomal doxorubicin
Maytansine
Antibodies
Immunoconjugates